Ageless Pep Academy Clinical Education · Licensed Prescribers

GLP-1 Cost-of-Care Analysis

GLP-1 Cost-of-Care Analysis — 12-Month Patient Economics

Framework for the cost conversation with weight-management patients considering branded vs. compounded GLP-1 pathways.

Market data — re-verify quarterly

Pricing subject to change. Last verified April 2026.

12-Month Cost Ranges (April 2026)

Pathway Monthly list Insurance OOP Cash monthly 12-mo cash
Wegovy (semaglutide branded) $1,350 $25–$200 with coupon $1,300–$1,600 $15,600–$19,200
Zepbound (tirzepatide branded) $1,059 $25–$550 with coupon $950–$1,100 via Lilly Direct $11,400–$13,200
Ozempic off-label $1,000 Usually denied non-T2DM Cash ≈ Wegovy Denied outside T2DM
Mounjaro off-label $1,070 Usually denied non-T2DM Cash ≈ Zepbound Denied outside T2DM
Compounded semaglutide (503A) $300–$600 N/A $300–$600 $3,600–$7,200 (regulatory risk)
Compounded tirzepatide (503A) $400–$700 N/A $400–$700 $4,800–$8,400 (regulatory risk)
Saxenda (liraglutide, daily) $1,400 $25–$200 $1,200–$1,400 $14,400–$16,800

Prior Authorization Success by Indication

Indication PA success Key documentation
T2DM (HbA1c >7.0) ~80% Failed metformin + lifestyle; HbA1c trend
Obesity (BMI ≥30) no comorbidity ~40% 6-month lifestyle attempt; BMI trend
Obesity (BMI ≥27) + comorbidity ~60% HTN, hyperlipidemia, OSA, NAFLD documented
CV risk reduction ~55% (increasing) Established ASCVD; non-diabetic
Pediatric obesity (≥12) ~50% Multidisciplinary program enrollment
Off-label <15% Usually denied

Appeal Pathways

  1. Peer-to-peer — 30–40% reversal rate with strong notes
  2. Formal written appeal — attach labs, comorbidity documentation, prior failed interventions
  3. External review — state insurance dept
  4. Alternative formulary — Wegovy ↔ Zepbound switch
  5. Manufacturer savings cards — commercial only
  6. Patient assistance programs — income-based full fill

The Cost Conversation (5-minute framework)

  1. Set expectations — chronic therapy, budget for 12+ months
  2. Pathway reveal — insurance / cash / compounded
  3. Shared decision — cost sensitivity vs regulatory certainty
  4. Discontinuation economics — STEP 4 / SURMOUNT-4 regain risk
  5. Maintenance option — reduced dose at goal

Document the cost conversation in the chart.

Pricing Stability Considerations

  • Compounded volatility — regulatory environment actively litigated; budget for mid-treatment transition (~3x cost shock)
  • Branded shortage risk — Zepbound was on shortage through 2024; have fallback plan
  • Insurance formulary changes — plans re-evaluate annually
  • Market dynamics — orforglipron (oral) 2026 filing may pressure injectable pricing

Cost-Effectiveness Evidence Base (2025)

The operational per-patient costs above are complemented by three independent published economic evaluations bracketing the current value verdict:

ICER 2025 Final Evidence Report

REG-ICER-Obesity-2025 – ICER Final Evidence Report Semaglutide Tirzepatide — Institute for Clinical and Economic Review, Final Report December 16, 2025.

  • Independent committee voted unanimously on positive net health benefit for injectable semaglutide, oral semaglutide, and tirzepatide
  • Majority of panelists found "high" long-term value for money at current pricing for all three agents
  • Health-benefit price benchmarks:
    • Injectable semaglutide: $9,100-$12,500/year
    • Oral semaglutide: $8,300-$11,400/year
    • Tirzepatide: $11,700-$16,100/year
  • Budget-impact warning: favorable per-patient value + very large eligible population creates payer budget stress

Hwang 2025 JAMA Health Forum — Lifetime Cost-Effectiveness

PMID 40085108 — Hwang JH, Laiteerapong N, Huang ES, Kim DD. JAMA Health Forum 2025;6(3):e245586.

  • Lifetime Markov cohort simulation in US adults eligible for anti-obesity pharmacotherapy
  • Tirzepatide: $197,023/QALY at current net prices
  • Semaglutide: $467,676/QALY at current net prices
  • At $100,000/QALY threshold: 0% probability of cost-effectiveness for either agent at current prices
  • Price concessions required to reach $100K/QALY: 30.5% (tirzepatide), 81.9% (semaglutide)
  • Naltrexone-bupropion was cost-saving (89.1% probability of cost-effectiveness)

Betensky 2025 Indication-Specific — Knee Osteoarthritis + Obesity

PMID 40953447 — Betensky DJ et al. Ann Intern Med 2025;178(11):1549-1560.

  • Decision-analytic cost-effectiveness in patients with knee OA + obesity
  • Tirzepatide ~$57,400/QALY in this subgroup
  • Substantially more favorable than general-population Hwang figure — arthroplasty-avoidance and other comorbidity offsets are larger
  • Teaching point: Indication-specific ICERs can differ substantially from general-population ICERs. Payer coverage criteria targeting high-comorbidity-burden patients (knee OA, severe OSA, MASH, CKD, established CVD) capture the populations where economic case is strongest

How to Reconcile ICER and Hwang for Payer and Patient Conversations

ICER and Hwang reach different value verdicts using different methodologies — both are legitimate:

Framework Verdict at current prices Anchor
ICER 2025 health-benefit benchmark "High" long-term value; benchmark ranges favor coverage Benchmark ranges $8K-$16K/yr
Hwang 2025 conventional $100K/QALY Not cost-effective at current net prices Per-QALY ICERs >$197K
Betensky 2025 indication-specific Favorable in knee OA + obesity subgroup ~$57K/QALY in subgroup

For patient counseling use the operational per-patient numbers (sections above). For payer conversations, formulary advocacy, or policy discussions, cite both ICER and Hwang plus indication-specific analyses like Betensky — give the full landscape rather than a single selected figure.

Related Peptides

Related References

Referenced in: Module 5 Lesson 5.4